Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.43 |
| ▸ | MAOB | P27338 | 8/20 | 0.43 |
| ▸ | KDM1A | O60341 | 8/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903571 | 0.92 | MAOA (0.50) | MAOAMAOBKDM1AFABP7FABP5 | |
| Trifluoroacetic Acid SCHEMBL15284348 | 0.92 | MAOA (0.41) | MAOAMAOBKDM1AFABP7FABP5 | |
| Trifluoroacetic Acid SCHEMBL15667517 | 0.86 | GAA (0.47) | MAOAMAOBKDM1A | |
| Trifluoroacetic Acid SCHEMBL13722853 | 0.80 | KDM1A (0.44) | MAOAMAOBKDM1A | |
| Trifluoroacetic Acid SCHEMBL14762539 | 0.80 | KDM1A (0.44) | MAOAMAOBKDM1A | |
| Trifluoroacetic Acid SCHEMBL13731052 | 0.78 | KDM1A (0.43) | MAOAMAOBKDM1A | |
| Trifluoroacetic Acid SCHEMBL14762804 | 0.78 | KDM1A (0.43) | MAOAMAOBKDM1A | |
| Trifluoroacetic Acid SCHEMBL15284412 | 0.78 | GAA (0.47) | MAOAMAOBKDM1ARORC | |
| SCHEMBL14762541 | 0.78 | KDM1A (0.40) | MAOAMAOBKDM1A | |
| SCHEMBL903428 | 0.77 | GAA (0.53) | MAOAMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-8992932-B2 | Binder-drug conjugates (ADCs) and use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | MAOA 3378/4885MAOB 2826/4885KDM1A 3254/4885 |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | MAOA 3777/4885MAOB 3457/4885KDM1A 3109/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | MAOA 3777/4885MAOB 3457/4885KDM1A 3109/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | MAOA 3378/4885MAOB 2826/4885KDM1A 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.